Mantle Cell Lymphoma

Copanlisib has been granted with a breakthrough therapy designation from the FDA for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib in mantle cell lymphoma.

In an interview with&nbsp;<em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the findings from the phase III BRIGHT trial for patients with MCL. He also highlighted the impact of BR in this patient population and other combinations under active investigation.

Andre Goy, MD, discusses the role of rituximab and bendamustine plus cytarabine as a treatment for patients with mantle cell lymphoma.

Andre Goy, MD,&nbsp;highlighted major controversies being investigated in the field of MCL in terms of patient subgroups and optimal management of each subpopulation.

Clinical outcomes were consistent among transplant-eligible patients with mantle cell lymphoma, regardless of which chemoimmunotherapy induction treatment was administered to the patient.

Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.

During a&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with mantle cell lymphoma in the clinic.

In a recent retrospective analysis, investigators found that initially observing patients with mantle cell lymphoma based solely on clinical criteria was an effective management strategy that did not&nbsp;compromise patient outcomes.

Long-term follow-up findings from the BRIGHT study support the use of bendamustine plus rituximab as a first-line treatment option for patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma.

Andre Goy, MD, discusses the agents he finds most promising for the treatment of patients with mantle cell lymphoma.

Jeff Sharman, MD,&nbsp;discusses the implications of real-world ibrutinib findings in mantle cell lymphoma and underscored the need for the development of more effective treatments for this patient population.

Although prognostic indices for mantle cell lymphoma can be useful in the classification of patients, it does little in guiding treatment decisions. Instead of relying on these indices, Simon Rule, MD, advocates for a watch-and-wait approach to managing certain patients&nbsp;with mantle cell lymphoma.

Andre Goy, MD,&nbsp;discusses some of the recent changes that have been seen in the treatment landscape for patients with MCL and some of the ways these subsets of patients are being identified in order to find the best treatment option for an individual patient.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

The treatment regimen of rituximab, bendamustine, bortezomib, and dexamethasone demonstrated activity and a manageable safety profile as a first-line therapy for patients with mantle cell lymphoma aged 65 years or older, according to findings from a prospective, multicenter phase II study.

The combination of ibrutinib and palbociclib appeared to be a feasible and active treatment regimen in patients with previously treated mantle cell lymphoma, according to findings from a phase I dose-finding study recently published in <em>Blood</em>.

Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.

The&nbsp;investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA&nbsp;for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy,&nbsp;BeiGene, the company manufacturing the agent, has announced.

Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.

Krish Patel, MD,&nbsp;discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Autologous hematopoietic cell transplantation consolidation after induction therapy may improve progression-free survival in younger, fit patients with mantle cell lymphoma, according to the results of a retrospective analysis recently published in the <em>Journal of Clinical Oncology. </em>

Jonathon B. Cohen, MD, MS, discussed his treatment considerations and decisions for treating patients with mantle cell lymphoma. Cohen made these decisions based on a case scenario of a patient with advanced-stage MCL.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Measuring circulating tumor DNA in the blood of patients with advanced MCL may be a viable way to predict how well they will respond to specific therapies, according to study findings reported at the 2018 ASH Annual Meeting.

In findings reported during the 2018 ASH Annual Meeting,&nbsp;brentuximab vedotin with conventional chemotherapy significantly improved&nbsp;progression-free survival compared with standard therapy for nonpediatric patients&nbsp;with stage III/IV Hodgkin lymphoma.

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab&nbsp; in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.

The shift in the pattern of care in mantle cell lymphoma to bendamustine and rituximab in the frontline has resulted in an improvement in event-free survival compared with the era in which R-CHOP dominated front-line treatment.